Skip to main content
Clinical Trials/NCT00930501
NCT00930501
Unknown
Not Applicable

Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients

Hadassah Medical Organization1 site in 1 country100 target enrollmentJune 2009
ConditionsInfertility

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infertility
Sponsor
Hadassah Medical Organization
Enrollment
100
Locations
1
Primary Endpoint
Anti mullerian hormone
Last Updated
16 years ago

Overview

Brief Summary

young female cancer patients have improving chances of survival. the main risk is a chronic damage to their ovarian reserve. This may lead to future infertility.

Detailed Description

our objective is to prospectively follow patients before and after their cancer treatment. this should help us learn of the gonadotoxicity of various treatments as well as be able to better consult these and future patients of the need of fertility preservation techniques.

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
December 2013
Last Updated
16 years ago
Study Type
Observational
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • all females prior and after chemotherapy

Exclusion Criteria

  • do not consent

Outcomes

Primary Outcomes

Anti mullerian hormone

Time Frame: 2 years

Secondary Outcomes

  • inhibin b(2 years)
  • antral follicle count(2 years)
  • FSH(2 years)
  • E2 and prog(2 years)
  • menstrual history(2 years)

Study Sites (1)

Loading locations...

Similar Trials